Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1975 5
1976 9
1977 3
1978 3
1981 1
1985 2
1986 5
1987 4
1988 4
1989 2
1990 4
1991 5
1992 2
1993 1
1994 1
1995 1
1996 1
1997 1
1998 1
2000 2
2001 2
2002 4
2003 3
2004 2
2005 4
2006 5
2007 9
2008 6
2009 14
2010 9
2011 18
2012 26
2013 30
2014 17
2015 25
2016 12
2017 10
2018 11
2019 15
2020 22
2021 20
2022 14
2023 15
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

336 results

Results by year

Filters applied: . Clear all
Page 1
Meningeal lymphatics affect microglia responses and anti-Aβ immunotherapy.
Da Mesquita S, Papadopoulos Z, Dykstra T, Brase L, Farias FG, Wall M, Jiang H, Kodira CD, de Lima KA, Herz J, Louveau A, Goldman DH, Salvador AF, Onengut-Gumuscu S, Farber E, Dabhi N, Kennedy T, Milam MG, Baker W, Smirnov I, Rich SS; Dominantly Inherited Alzheimer Network; Benitez BA, Karch CM, Perrin RJ, Farlow M, Chhatwal JP, Holtzman DM, Cruchaga C, Harari O, Kipnis J. Da Mesquita S, et al. Nature. 2021 May;593(7858):255-260. doi: 10.1038/s41586-021-03489-0. Epub 2021 Apr 28. Nature. 2021. PMID: 33911285 Free PMC article.
Alzheimer's disease (AD) is the most prevalent cause of dementia(1). Although there is no effective treatment for AD, passive immunotherapy with monoclonal antibodies against amyloid beta (Abeta) is a promising therapeutic strategy(2,3). ...
Alzheimer's disease (AD) is the most prevalent cause of dementia(1). Although there is no effective treatment for AD, passive immunot …
An astrocyte BMAL1-BAG3 axis protects against alpha-synuclein and tau pathology.
Sheehan PW, Nadarajah CJ, Kanan MF, Patterson JN, Novotny B, Lawrence JH, King MW, Brase L, Inman CE, Yuede CM, Lee J, Patel TK, Harari O, Benitez BA, Davis AA, Musiek ES. Sheehan PW, et al. Neuron. 2023 Aug 2;111(15):2383-2398.e7. doi: 10.1016/j.neuron.2023.05.006. Epub 2023 Jun 13. Neuron. 2023. PMID: 37315555
TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4.
Gratuze M, Schlachetzki JCM, D'Oliveira Albanus R, Jain N, Novotny B, Brase L, Rodriguez L, Mansel C, Kipnis M, O'Brien S, Pasillas MP, Lee C, Manis M, Colonna M, Harari O, Glass CK, Ulrich JD, Holtzman DM. Gratuze M, et al. Neuron. 2023 Jan 18;111(2):202-219.e7. doi: 10.1016/j.neuron.2022.10.022. Epub 2022 Nov 10. Neuron. 2023. PMID: 36368315 Free PMC article.
In addition to tau and Abeta pathologies, inflammation plays an important role in Alzheimer's disease (AD). Variants in APOE and TREM2 increase AD risk. ApoE4 exacerbates tau-linked neurodegeneration and inflammation in P301S tau mice and removal of microglia blocks tau-de …
In addition to tau and Abeta pathologies, inflammation plays an important role in Alzheimer's disease (AD). Variants in APOE and TREM …
Single-nucleus RNA-sequencing of autosomal dominant Alzheimer disease and risk variant carriers.
Brase L, You SF, D'Oliveira Albanus R, Del-Aguila JL, Dai Y, Novotny BC, Soriano-Tarraga C, Dykstra T, Fernandez MV, Budde JP, Bergmann K, Morris JC, Bateman RJ, Perrin RJ, McDade E, Xiong C, Goate AM, Farlow M; Dominantly Inherited Alzheimer Network (DIAN); Sutherland GT, Kipnis J, Karch CM, Benitez BA, Harari O. Brase L, et al. Nat Commun. 2023 Apr 21;14(1):2314. doi: 10.1038/s41467-023-37437-5. Nat Commun. 2023. PMID: 37085492 Free PMC article.
The Staudinger Ligation.
Bednarek C, Wehl I, Jung N, Schepers U, Bräse S. Bednarek C, et al. Chem Rev. 2020 May 27;120(10):4301-4354. doi: 10.1021/acs.chemrev.9b00665. Epub 2020 May 1. Chem Rev. 2020. PMID: 32356973 Review.
Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer.
Corcoran RB, André T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G, Muro K, Gordon MS, Tabernero J, Yaeger R, O'Dwyer PJ, Humblet Y, De Vos F, Jung AS, Brase JC, Jaeger S, Bettinger S, Mookerjee B, Rangwala F, Van Cutsem E. Corcoran RB, et al. Cancer Discov. 2018 Apr;8(4):428-443. doi: 10.1158/2159-8290.CD-17-1226. Epub 2018 Feb 5. Cancer Discov. 2018. PMID: 29431699 Free PMC article. Clinical Trial.
Dual-stimuli-responsive microparticles.
Sokolovskaya E, Rahmani S, Misra AC, Bräse S, Lahann J. Sokolovskaya E, et al. ACS Appl Mater Interfaces. 2015 May 13;7(18):9744-51. doi: 10.1021/acsami.5b01592. Epub 2015 Apr 30. ACS Appl Mater Interfaces. 2015. PMID: 25886692 Free PMC article.
Chemical Synthesis of Glycosaminoglycans.
Mende M, Bednarek C, Wawryszyn M, Sauter P, Biskup MB, Schepers U, Bräse S. Mende M, et al. Chem Rev. 2016 Jul 27;116(14):8193-255. doi: 10.1021/acs.chemrev.6b00010. Epub 2016 Jul 13. Chem Rev. 2016. PMID: 27410264 Review.
Because of the potential therapeutic application of GAG polymers, fragments, and also derivatives toward different diseases (e.g., heparin derivatives against Alzheimer's disease), there is a continual growing demand for new chemical syntheses, which suffice the high claim …
Because of the potential therapeutic application of GAG polymers, fragments, and also derivatives toward different diseases (e.g., heparin d …
Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600-Mutant Unresectable or Metastatic Melanoma.
Dummer R, Long GV, Robert C, Tawbi HA, Flaherty KT, Ascierto PA, Nathan PD, Rutkowski P, Leonov O, Dutriaux C, Mandalà M, Lorigan P, Ferrucci PF, Grob JJ, Meyer N, Gogas H, Stroyakovskiy D, Arance A, Brase JC, Green S, Haas T, Masood A, Gasal E, Ribas A, Schadendorf D. Dummer R, et al. J Clin Oncol. 2022 May 1;40(13):1428-1438. doi: 10.1200/JCO.21.01601. Epub 2022 Jan 14. J Clin Oncol. 2022. PMID: 35030011 Free PMC article. Clinical Trial.
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Váraljai R, Zimmer L, Al-Matary Y, Kaptein P, Albrecht LJ, Shannan B, Brase JC, Gusenleitner D, Amaral T, Wyss N, Utikal J, Flatz L, Rambow F, Reinhardt HC, Dick J, Engel DR, Horn S, Ugurel S, Sondermann W, Livingstone E, Sucker A, Paschen A, Zhao F, Placke JM, Klose JM, Fendler WP, Thommen DS, Helfrich I, Schadendorf D, Roesch A. Váraljai R, et al. Nat Cancer. 2023 Sep;4(9):1292-1308. doi: 10.1038/s43018-023-00610-2. Epub 2023 Jul 31. Nat Cancer. 2023. PMID: 37525015 Free PMC article.
336 results